Factors related to different reasons for antipsychotic drug discontinuation in the treatment of schizophrenia: A naturalistic 18-month follow-up study

Psychiatry Research

Volumn 200, Issue 2-3, 2012, Pages 96-101

  Vita, Antonio ^a,b   Barlati, Stefano ^a   Deste, Giacomo ^a,b   Corsini, Paola ^a   De Peri, Luca ^b   Sacchetti, Emilio ^a,b  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Antipsychotic treatment; Effectiveness; Efficacy; Patient's Compliance with treatment; Side effects

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; COMMUNITY MENTAL HEALTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE DELIVERY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTPATIENTS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT FAILURE; WITHHOLDING TREATMENT;

EID: 84872424354     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.07.006     Document Type: Article

References (30)

1. American Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision. American Psychiatric Association, Washington DC.
2. Ascher-Svanum H., Zhu B., Faries D., Landbloom R., Swartz M., Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006, 21:6-8.
3. Barbui C., Nosè M., Bindman J., Schene A., Becker T., Mazzi M.A., Kikkert M., Camara J., Born A., Tansella M. Sex differences in the subjective tolerability of antipsychotic drugs. Journal of Clinical Psychopharmacology 2005, 25(6):521-526.
4. Crespo-Facorro B., Pérez-Iglesias R.O., Mata I., Ramirez-Bonilla M., Martínez-Garcia O., Pardo-Garcia G., Caseiro O., Pelayo-Terán J.M., Vázquez-Barquero J.L. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. Journal of Psychopharmacology 2011, 25(6):744-754.
5. Day J.C., Bentall R.P., Roberts C., Randall F., Rogers A., Cattell D., Healy D., Rae P., Power C.. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Archives of General Psychiatry 2005, 62:717-724.
6. Fattore G., Percudani M., Pugnoli C., Contini A., Beecham J. Mental health care in Italy: organisational structure, routine clinical activity and costs of community psychiatric service in Lombardy Region. International Journal of Social Psychiatry 2000, 46:250-265.
7. Goff D.C., Hill M., Freudenreich O. Treatment adherence in schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 2011, 72(4):e13.
8. Haro J.M., Novick D., Belger M., Jones P.B. Antipsychotic type and correlates of any antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. European Psychiatry 2006, 21:41-47.
9. Haro J.M., Novick D., Suarez D., Roca M. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. Journal of Psychiatric Research 2009, 43(3):265-273.
10. Jönsson E.G., Saetre P., Vares M., Strålin P., Levander S., Lindström E. Use of antipsychotics - an analysis of lifetime treatment in 66 patients with psychoses. Psychiatry Research 2011, 187(1-2):80-88.
11. Kikkert M.J., Schene A.H., Koeter M.W., Robson D., Born A., Helm H., Nose M., Goss C., Thornicroft G., Gray R.J. Medication adherence in schizophrenia: exploring patients', carers', and professionals' views. Schizophrenia Bulletin 2006, 32(2):786-794.
12. Køster A., Lajer M., Lindhardt A., Rosenbaum B. Gender differences in first episode psychosis. Social Psychiatry and Psychiatric Epidemiology 2008, 43(12):940-946.
13. Kumra S., Oberstar J.V., Sikich L., Findling R.L., McClellan J.M., Vinogradov S., Charles Schulz S. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophrenia Bulletin 2008, 34(1):60-71.
14. Leucht S., Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. Journal of Clinical Psychiatry 2006, 67(5):3-8.
15. Levine S.Z., Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophrenia Bulletin 2010, 36(3):624-632.
16. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005, 353:1209-1223.
17. Lora A. Il Sistema di Salute Mentale di Regione Lombardia 2010, Direzione Generale Sanità Regione Lombardia, Milan.
18. Mullins C.D., Obeidat N.A., Cuffel B.J., Naradzay J., Loebel A.D. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophrenia Research 2008, 98(1-3):8-15.
19. Percudani M., Barbui C., Beecham J., Knapp M. Routine outcome monitoring in clinical practice: service and non-service costs of psychiatric patients attending a Community Mental Health Centre in Italy. European Psychiatry 2004, 19(8):469-477.
20. Percudani M., Fattore G., Belloni G.C., Gerzeli S., Contini A. Service utilisation and costs of first-contact patients in a community psychiatric service in Italy. European Psychiatry 2002, 17(8):434-442.
21. Piano Regionale Salute Mentale (Regional Mental Health Plan), 2004. Delibera giunta regionale Lombardia n. 7/17513, Milan.
22. Pourcher E., Baruch P., Bouchard R.H., Filteau M.J., Bergeron D. Neuroleptic associated tardive dyskinesias in young people with psychoses. British Journal of Psychiatry 1995, 166(6):768-772.
23. Reichert A., Kreiker S., Mehler-Wex C., Warnke A. The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child and Adolescent Psychiatry and Mental Health 27 2008, 2(1):6.
24. Richardson M.A., Haugland G., Craig T.J. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. American Journal of Psychiatry 1991, 148(10):1322-1328.
25. Seeman M.V. Gender differences in the prescribing of antipsychotic drugs. American Journal of Psychiatry 2004, 161(8):1324-1333.
26. Smith S. Gender differences in antipsychotic prescribing. International Review of Psychiatry 2010, 22(5):472-484.
27. SPSS Inc. SPSS 13.0 Applications Guide 2004, SPSS Inc., Chicago, IL.
28. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., Lieberman J.A. The National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 2003, 29(1):15-31.
29. Tiihonen J., Wahlbeck K., Lönnqvist J., Klaukka T., Ioannidis J.P., Volavka J., Haukka J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. British Medical Journal 2006, 29(333(7561)):224.
30. Vita A., Corsini P., Bonomi S., Sacchetti E. Factors affecting antipsychotic drug discontinuation in the treatment of schizophrenia: evidence from a naturalistic, retrospective, 18-month follow-up study. Schizophrenia Research 2008, 104:302-304.